OPKO Health, Inc. Noncontrolling Interest, Decrease from Deconsolidation
OPKO Health, Inc. (OPK) reported Noncontrolling Interest, Decrease from Deconsolidation of $6.40 million for the 12-month period ending 2015-12-31, per its 8-K filed 2019-01-29.
Discontinued › Shareholders' Equity
us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation · last filed 2019-01-29
| Period end | Noncontrolling Interest, Decrease from Deconsolidation 12 month |
|---|---|
| 2015-12-31 | $6.40M 8-K · filed 2019-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |